Galmed Pharmaceuticals buys Colospan in deal valued up to $5.3 million

• Galmed Pharmaceuticals agreed to buy Colospan, making the business a wholly owned subsidiary upon closing on June 22, 2026.
• Consideration totals US$ 3.3 million in cash, split among Colospan shareholders and certain SAFE investors.
• Deal includes up to US$ 2 million earnout tied to net revenue sales starting July 1, 2027, with no payments on the first US$ 5 million.
• Earnout rates set at 7% for sales from US$ 5 million to US$ 12 million, rising to 9% above US$ 12 million, capped at US$ 2 million.
• 7.5% of the cash consideration to be held in escrow for 12 months to cover potential post-closing indemnification claims.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galmed Pharmaceuticals Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-032504), on July 08, 2026, and is solely responsible for the information contained therein.